Okay, let's tackle this question. The user is asking about monoclonal antibodies targeting CD20 and which one is the exception. First, I need to recall which monoclonal antibodies are specific for CD20. CD20 is a B-cell marker, so these antibodies are used in B-cell lymphomas and autoimmune diseases.

Common CD20-targeting monoclonals include rituximab, obinutuzumab, ofatumumab, and maybe others like veltuzumab. But wait, there's also obinutuzumab, which is a glycoengineered version. Now, I should think about other monoclonal antibodies. For example, alemtuzumab targets CD52, which is on T and B cells. That's used in CLL and MS. So if one of the options is alemtuzumab, that would be the exception here.

Let me check the options again. The question says "except," so the correct answer is the one that's not against CD20. If the options include alemtuzumab, rituximab, obinutuzumab, and ofatumumab, then alemtuzumab is the correct answer. Alternatively, maybe there's another one like trastuzumab, which targets HER2. But trastuzumab isn't CD20. So if the options include trastuzumab, that would be the exception. However, the user didn't provide the options, but the correct answer is given as something. Wait, the user provided the correct answer as, for example, option A being the correct one. Since the user didn't specify the options, maybe the correct answer is alemtuzumab. Let me confirm. Alemtuzumab targets CD52, rituximab CD20. So if the options include alemtuzumab and others like rituximab, then alemtuzumab is the exception.

I need to make sure about the other CD20 antibodies. Let me list them: rituximab, obinutuzumab, ofatumumab, and veltuzumab. So any other antibody targeting a different antigen would be the correct answer here. So the user is looking for an antibody that's not targeting CD20. So the core concept is CD20 targeting monoclonal antibodies. The correct answer is the one that targets a different antigen. The wrong options are CD20-targeting ones. The clinical pearl is knowing which monoclonals target CD20 versus others like CD52 or HER2.

**Core Concept**
CD20 is a surface antigen expressed on B-cells, targeted by monoclonal antibodies like rituximab, obinutuzumab, and ofatumumab. These agents induce B-cell depletion in conditions such as B-cell lymphomas and autoimmune diseases.

**Why the Correct Answer is Right**
Alemtuzumab is a monoclonal antibody targeting CD52, an antigen present on T and B cells, not CD20. It is used in chronic lymphocytic leukemia and multiple sclerosis. Its mechanism involves complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

**Why Each Wrong Option is Incorrect**
**Option A:** *Rit

✓ Correct Answer: D. Brentuximab